Passa al contenuto
Merck

Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.

Acta cardiologica (2014-05-03)
Daisy Puttevils, Philip De Vusser, Piet Geusens, Jo Dens
ABSTRACT

Patients with established rheumatoid arthritis (RA) have a higher cardiovascular morbidity and mortality in comparison with the general population. It is considered to be an independent risk factor for cardiovascular disease. The purpose of this article is to describe the mechanisms responsible for accelerated atherogenesis in RA patients and to give an overview of the effects of different RA therapies (methotrexate, TNF antagonists and other biologicals).

MATERIALI
Numero di prodotto
Marchio
Descrizione del prodotto

Sigma-Aldrich
Metotrexato, ≥98% (HPLC), powder
Sigma-Aldrich
Metotrexato, powder, BioReagent, suitable for cell culture, ≥98% (HPLC)
Sigma-Aldrich
Metotrexato, meets USP testing specifications
SAFC
Methotrexate
Supelco
Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Methotrexate solution, 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®
Methotrexate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Metotrexato, ≥99.0% (sum of enantiomers, HPLC)
Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard
Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard